BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

Cell Reports

Volumn 16, Issue 11, 2016, Pages 2829-2837

  Zhu, Hengrui ^a   Bengsch, Fee ^a   Svoronos, Nikolaos ^a   Rutkowski, Melanie R ^a   Bitler, Benjamin G ^a   Allegrezza, Michael J ^a   Yokoyama, Yuhki ^a   Kossenkov, Andrew V ^a   Bradner, James E ^b   Conejo Garcia, Jose R ^a   Zhang, Rugang ^a  

^a WISTAR INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; PROGRAMMED DEATH 1 LIGAND 1; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; BROMODOMAIN AND EXTRA-TERMINAL DOMAIN PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG TARGETING; FEMALE; GENETIC TRANSCRIPTION; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE COURSE; DRUG EFFECTS; GENETICS; HUMAN; IMMUNITY; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD274; AZEPINES; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNITY; MICE, INBRED C57BL; NEOPLASMS; NUCLEAR PROTEINS; PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRIAZOLES;

EID: 84991672070     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.08.032     Document Type: Article

References (23)

1. Abiko, K., Mandai, M., Hamanishi, J., Yoshioka, Y., Matsumura, N., Baba, T., Yamaguchi, K., Murakami, R., Yamamoto, A., Kharma, B., et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin. Cancer Res. 19 (2013), 1363–1374.
2. Adams, J.L., Smothers, J., Srinivasan, R., Hoos, A., Big opportunities for small molecules in immuno-oncology. Nat. Rev. Drug Discov. 14 (2015), 603–622.
3. Baratta, M.G., Schinzel, A.C., Zwang, Y., Bandopadhayay, P., Bowman-Colin, C., Kutt, J., Curtis, J., Piao, H., Wong, L.C., Kung, A.L., et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc. Natl. Acad. Sci. USA 112 (2015), 232–237.
4. Belkina, A.C., Nikolajczyk, B.S., Denis, G.V., BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J. Immunol. 190 (2013), 3670–3678.
5. Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih, IeM., Conejo-Garcia, J.R., et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21 (2015), 231–238.
6. Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
7. Conejo-Garcia, J.R., Benencia, F., Courreges, M.C., Kang, E., Mohamed-Hadley, A., Buckanovich, R.J., Holtz, D.O., Jenkins, A., Na, H., Zhang, L., et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 10 (2004), 950–958.
8. Cubillos-Ruiz, J.R., Engle, X., Scarlett, U.K., Martinez, D., Barber, A., Elgueta, R., Wang, L., Nesbeth, Y., Durant, Y., Gewirtz, A.T., et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J. Clin. Invest. 119 (2009), 2231–2244.
9. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004), 942–949.
10. Filippakopoulos, P., Knapp, S., Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13 (2014), 337–356.
11. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O., Morse, E.M., Keates, T., Hickman, T.T., Felletar, I., et al. Selective inhibition of BET bromodomains. Nature 468 (2010), 1067–1073.
12. Goundiam, O., Gestraud, P., Popova, T., De la Motte Rouge, T., Fourchotte, V., Gentien, D., Hupé, P., Becette, V., Houdayer, C., Roman-Roman, S., et al. Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma. Int. J. Cancer 137 (2015), 1890–1900.
13. Mahoney, K.M., Rennert, P.D., Freeman, G.J., Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14 (2015), 561–584.
14. Melero, I., Berman, D.M., Aznar, M.A., Korman, A.J., Pérez Gracia, J.L., Haanen, J., Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15 (2015), 457–472.
15. Mok, S.C., Bonome, T., Vathipadiekal, V., Bell, A., Johnson, M.E., Wong, K.K., Park, D.C., Hao, K., Yip, D.K., Donninger, H., et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16 (2009), 521–532.
16. Naidoo, J., Page, D.B., Li, B.T., Connell, L.C., Schindler, K., Lacouture, M.E., Postow, M.A., Wolchok, J.D., Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26 (2015), 2375–2391.
17. Nesbeth, Y., Scarlett, U., Cubillos-Ruiz, J., Martinez, D., Engle, X., Turk, M.J., Conejo-Garcia, J.R., CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res. 69 (2009), 6331–6338.
18. Nicodeme, E., Jeffrey, K.L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. Suppression of inflammation by a synthetic histone mimic. Nature 468 (2010), 1119–1123.
19. Scarlett, U.K., Rutkowski, M.R., Rauwerdink, A.M., Fields, J., Escovar-Fadul, X., Baird, J., Cubillos-Ruiz, J.R., Jacobs, A.C., Gonzalez, J.L., Weaver, J., et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 209 (2012), 495–506.
20. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
21. Webb, J.R., Milne, K., Kroeger, D.R., Nelson, B.H., PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol. Oncol. 141 (2016), 293–302.
22. Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H.P., Vendetti, F., Vancriekinge, W., Demeyer, T., Du, Z., Parsana, P., et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4 (2013), 2067–2079.
23. Zou, W., Wolchok, J.D., Chen, L., PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med., 8, 2016, 328rv4.